Enflonsia in Oman

Enflonsia - overview

Enflonsia (clesrovimab-cfor) is manufactured by Merck and indicated for Chronic pain, OUT OF SCOPE (fentanyl class / Schedule II; PlatformCo does not handle controlled substances. Product-name mapping also uncertain, verify FDA label before any future consideration by Fatima's entity.). It is a long-acting monoclonal antibody (single 105 mg intramuscular injection) approved by the US FDA in 2025 and may be accessible to patients in Oman through a Named Patient Program or personal-import pathway.

Access in Oman

Oman's MoH operates a personal-import pathway; volumes are smaller but the pathway is functional for rare-disease and specialty needs.

How Reserve Meds coordinates access in Oman

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Oman-specific eligibility.
3. Treating physician in Oman issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Enflonsia from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Oman.

Typical timeline for Oman

End-to-end, most requests are completed in 2-6 weeks. Oman's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Oman ask

• Is the pathway legal in Oman? Yes - it operates under Oman's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Oman able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Enflonsia in Oman

Join the Enflonsia waitlist